| Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone. | |
MedLine Citation:
|
PMID: 11773385 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Reverse genetics was used to develop a two-component, trivalent live attenuated vaccine against human parainfluenza virus type 3 (HPIV3) and respiratory syncytial virus (RSV) subgroups A and B. The backbone for each of the two components of this vaccine was the attenuated recombinant bovine/human PIV3 (rB/HPIV3), a recombinant BPIV3 in which the bovine HN and F protective antigens are replaced by their HPIV3 counterparts (48). This chimera retains the well-characterized host range attenuation phenotype of BPIV3, which appears to be appropriate for immunization of young infants. The open reading frames (ORFs) for the G and F major protective antigens of RSV subgroup A and B were each placed under the control of PIV3 transcription signals and inserted individually or in homologous pairs as supernumerary genes in the promoter proximal position of rB/HPIV3. The level of replication of rB/HPIV3-RSV chimeric viruses in the respiratory tract of rhesus monkeys was similar to that of their parent virus rB/HPIV3, and each of the chimeras induced a robust immune response to both RSV and HPIV3. RSV-neutralizing antibody titers induced by rB/HPIV3-RSV chimeric viruses were equivalent to those induced by infection with wild-type RSV, and HPIV3-specific antibody responses were similar to, or slightly less than, after infection with the rB/HPIV3 vector itself. This study describes a novel vaccine strategy against RSV in which vaccine viruses with a common attenuated backbone, specifically rB/HPIV3 derivatives expressing the G and/or F major protective antigens of RSV subgroup A and of RSV subgroup B, are used to immunize by the intranasal route against RSV and HPIV3, which are the first and second most important viral agents of pediatric respiratory tract disease worldwide. |
Authors:
|
Alexander C Schmidt; Daniel R Wenzke; Josephine M McAuliffe; Marisa St Claire; William R Elkins; Brian R Murphy; Peter L Collins |
Related Documents
:
|
1666095 - Development of a whole killed feline leukemia virus vaccine. 8212825 - Vaccination with a heterologous respiratory syncytial virus chimeric fg glycoprotein de... 15747245 - Identification of a recombinant live attenuated respiratory syncytial virus vaccine can... 9066965 - Do postvaccinal sarcomas occur in australian cats? 19196195 - Pertussis vaccination in newborns. 17124785 - Sublingual vaccines based on wild-type recombinant allergens. |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. |
Journal Detail:
|
Title: Journal of virology Volume: 76 ISSN: 0022-538X ISO Abbreviation: J. Virol. Publication Date: 2002 Feb |
Date Detail:
|
Created Date: 2002-01-04 Completed Date: 2002-02-12 Revised Date: 2013-04-18 |
Medline Journal Info:
|
Nlm Unique ID: 0113724 Medline TA: J Virol Country: United States |
Other Details:
|
Languages: eng Pagination: 1089-99 Citation Subset: IM |
Affiliation:
|
Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA. aschmidt@niaid.nih.gov |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Antibodies, Viral / biosynthesis, blood, immunology Antigens, Viral / genetics, immunology Base Sequence Cattle Cell Line Cercopithecus aethiops DNA, Viral Disease Models, Animal Genetic Vectors* / genetics, physiology Genome, Viral HN Protein / genetics, immunology Humans Immunity, Mucosal / immunology Macaca mulatta Molecular Sequence Data Mutagenesis, Insertional / methods Open Reading Frames Parainfluenza Vaccines / genetics, immunology* Parainfluenza Virus 3, Bovine* / genetics, physiology Parainfluenza Virus 3, Human / genetics, immunology* Respiratory Syncytial Virus Infections / immunology*, prevention & control Respiratory Syncytial Virus Vaccines / genetics, immunology* Respiratory Syncytial Viruses / genetics, immunology* Respirovirus Infections / immunology*, prevention & control Transcription, Genetic Tumor Cells, Cultured Vaccination Vaccines, Attenuated / genetics, immunology Vaccines, DNA / genetics, immunology* Vero Cells Viral Fusion Proteins / genetics, immunology Viral Proteins / genetics, immunology Virus Replication |
| Grant Support | |
ID/Acronym/Agency:
|
AI-000030/AI/NIAID NIH HHS; AI-000087/AI/NIAID NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Viral; 0/Antigens, Viral; 0/DNA, Viral; 0/HN Protein; 0/Parainfluenza Vaccines; 0/Respiratory Syncytial Virus Vaccines; 0/Vaccines, Attenuated; 0/Vaccines, DNA; 0/Viral Fusion Proteins; 0/Viral Proteins; 109300-94-9/F protein, parainfluenza virus 3 |
| Comments/Corrections | |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The cyclin-dependent kinase inhibitor roscovitine inhibits the transactivating activity and alters t...
Next Document: Artificial extension of the adenovirus fiber shaft inhibits infectivity in coxsackievirus and adenov...